Free Submission Public Relations &
Deutsch English


"EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022" Published

Print article Print article
2013-02-26 01:55:00 - Fast Market Research recommends "EpiCast Report: Dyslipidemia Epidemiology Forecast to 2022" from GlobalData, now available

Dyslipidemia is a condition in which one or more blood lipid levels are abnormal. It is an underdiagnosed, undertreated, and highly prevalent disease worldwide. Prevalent cases of dyslipidemia in the nine markets is expected to increase from 443.8 million cases in 2012 to 522.0 million cases in 2022 at the rate of 1.76% per year. Factors that influence prevalence include risk factors, disease management, awareness of disease status, population growth, and changes in diagnosis and treatment guidelines. In 2012, India had the highest number of prevalent dyslipidemia cases in the nine major markets at 192.7 million, followed by China at 84.7 million, and the US at 48.6 million. These three countries will continue to dominate in the number of prevalent

cases through 2022, during which they will be expected to contribute to 65.6% of the total 522.0 million prevalent cases of all markets combined. This trend is driven mainly by the large populations as the prevalence rates are relatively low in these countries. EU countries such as Germany, Spain, and the UK had prevalence rates that were two or three times that of the other countries. The sex gap for dyslipidemia prevalent cases in the nine markets is not significantly high in this analysis. However, age-group analysis showed that dyslipidemia is most prevalent in people ages 40-69 years. The prevalence of dyslipidemia is also affected by the diagnosis and treatment guidelines followed by each country. An update in the ATP guidelines, ATP-IV, is expected to be released at the end of 2012 or 2013 and may impact the prevalent cases forecast.

Full Report Details at
- ..


* The dyslipidemia EpiCast Report provide an overview of the risk factors and global trends of dyslipidemia in seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to two emerging markets-India and China.
* It includes a 10-year epidemiological forecast of dyslipidemia prevalence segmented by sex and age (by 5-year age groups beginning at 20 years of age) to 2022.

Reasons to buy

* Develop business strategies by understanding the historical trends of global dyslipidemia market as well as the risk factors and treatment and diagnosis guidelines that shape the trends.
* Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
* Organize sales and marketing efforts by identifying the age group and gender that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Epidemiology
3.1 Disease Background and Definition
3.2 Common Diagnostic Criteria for Dyslipidemia
3.2.1 NCEP-ATPIII Guidelines
3.2.2 ESC/ EAS Guidelines
3.3 Risk Factors and Comorbidities
3.3.1 Sedentary Lifestyle, High Caloric and Alcohol Intake are Associated with Dyslipidemia
3.3.2 Sex Disparity in Dyslipidemia Treatment is Large, but the Reasons are Unclear
3.3.3 Dyslipidemia is a Strong Risk Factor for CVD
3.4 Secondary Causes of Dyslipidemia
3.5 Global Trends
3.5.1 United States
3.5.2 Europe
3.5.3 Asia
3.6 Forecast Methodology
3.6.1 Sources Used
3.6.2 Forecast Assumptions and Methods
3.7 Epidemiology Forecast (2012-2022)
3.7.1 Prevalent Cases of Dyslipidemia
3.7.2 Age-Specific Prevalent Cases of Dyslipidemia
3.7.3 Sex-Specific Prevalent Cases of Dyslipidemia
3.8 Discussion
3.8.1 Conclusions Regarding Epidemiological Trends
3.8.2 Limitations of the Analysis
3.8.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
4.5 Contact Us
4.6 Disclaimer

List of Tables

1.1 List of Tables
Table 1: NCEP-ATP III Classification of TC, LDL-C, HDL-C, and TG (mg/dL)
Table 2: Nine Major Markets, Sources of Prevalent Data Used in the Epidemiology Forecast
Table 3: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages ≥20, Men and Women, N, Selected Years, 2012-2022
Table 4: Nine Major Markets, Prevalent Cases of Dyslipidemia, By Age*, Men and Women, N (Row %), 2012
Table 5: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages ≥20 Years, By Sex, N (Row %), 2012

List of Figures

1.2 List of Figures
Figure 1: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages ≥20, Men and Women, N, Select Years, 2012-2022
Figure 2: Nine Major Markets, Prevalent Cases of Dyslipidemia, By Age*, Men and Women, N, 2012
Figure 3: Nine Major Markets, Prevalent Cases of Dyslipidemia, Ages ≥20 Years, By Sex, N, 2012

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact | BidVertiser